Updated on 5 February 2015
Many significant agreements and MoUs were signed between government, national and international organizations at the event
Singapore: The three day BioAsia 2015, concluded on the 4th February, 2015. The event saw significant participation form the industry leaders, government officilas, regulators and academic experts.
The sessions covered important topics like the efforts to prevent and control NCDs from Government of India, preventing blindness due to diabetes and hypertension, role of corporate in management and prevention of NCDs, bringing clinical research into the next decade: Innovations and Global Strategies, Role of Information Technology to help clinicians and better healthcare management.
Speaking on this occasion, Mr. Shakthi Nagappan, CEO of BioAsia said, "This edition of BioAsia has been intrumental in bringing together the stakeholders of Biotech, Healthcare, Pharma and IT industry. Partnerships like TSIIC & China Medical City and FABA and Thailand Center of Excellence for lifesciences would help each of them resulting better medical facilities for people. Around 1,350 delegates registered at BioAsia 2015 during these 3 days representing 50 countries. The buyer-seller meets organized at BioAsia 2015 would also help the Indian smaller manufacturers to learn and understand the technological inventions in medical devices making it cheaper for local consumers."
The Indian state of Telengana unveiled a Lifesciences policy at the BioAsia 2015 event and categorized liofesciences as one of 14 priority industrial sectors encompassing biotechnology, bulk drugs, formulations, vaccines, nutraceuticals, biological, biosimilars, incubation centers, R&D facilities and medical devices to attract an investment of Rs.21,000 crore.
The Telengana government also announced plans to set up a pharma city on 11,000 acres on the outskirts of Hyderabad, to support the development of lifesciences park by private agencies also.
An industrial park for medical devices will also be set up in Sultanpur, Medak district, India. The Genome Valley is also to be expanded by another 200 acres as biotech park phase IV in Mulugu, in the same district.